in Ontario (ONT) and to develop recommendations to ensure all patients to have equitable access to MR-guided brachytherapy (MRgBT) for cervical cancer. Methods: A qualitative phone interview was designed by the GYN CoP working group to survey the current state of ccBT in the province. Questions were developed to inquire about the current use of image-guided ccBT and the associated referral processes, the usage of MR imaging in ccBT and the current use of imageguided interstitial GYN BT. All ONT cancer centres offering radiation treatments to GYN cancers were included. Two group members conducted and audio recorded the telephone interviews from May to November 2015 and analyzed all recordings and summarized the data. Results: Thirteen (n = 13) ONT cancer centres were interviewed. Of these, three centres do not offer ccBT, five centres offer CTguided ccBT, four centres offer a combination of CT-MR-guided ccBT and one centre offers strictly MR-guided ccBT. The three centres that do not offer ccBT have established referral processes with three tertiary cancer centres in ONT respectively. However, there is no standardized referral process, referral timing, or method of communication. Other practices vary throughout the centres. Three of 13 centres suggested developing a file portal to standardize and facilitate the sharing of external beam and BT plans, distributions and images. All CTguided ccBT centres except one have plans to develop MRgBT. The tertiary centres mentioned above are also the only centres that offer interstitial GYN BT. They are located in the southwestern part of the province. Of these, one centre offers CT-guided and two centres offer MR-guided interstitial GYN BT. There is currently no standardized guideline to identify patient candidates for interstitial GYN BT. Conclusions: This study demonstrated that models of shared care exist and are functioning in ONT. While referral processes are functioning well, some areas represent opportunities for improvement. Future work is needed by the GYN CoP to improve referral processes and to develop consensus on indications for interstitial brachytherapy. This will ensure all patients in ONT have access to this high quality brachytherapy. Patients had treatment plans created, with a CT reference marker placed on the medial aspect of the nipple and tattoos consistent with standard institutional practice for external beam radiation treatments (EBRT). For patients receiving PBSI, skin markings were placed on the patient's breast to map the implant, on the morning of the procedure. The interval from planning CT to implant date was two to four weeks. For this study, mark-up and delivery data were documented and deviations between planning CT and implant data for PBSI, were reviewed to determine the most reliable measurements for patient positioning and mark-up. Results: Among 40 patients initially assessed for PBSI, 27 proceeded to implant and 13 ineligible patients (seroma too large or close to skin) had EBRT. The EBRT set-up tattoos used in PBSI were observed to have significant deviations from the planning CT, due to the variation in arm placement between the two treatment modalities. Measurements to determine the fiducial entry point referencing the nipple marker were determined to have a mean deviation of < 1 mm while those from the observation of a PBSI operating room procedure; 4) Active involvement of the participants in practice sessions with phantoms and realistic operating room scenarios; 5) Wrap up session: opportunity to share experiences and problem solve. Group discussion on how to translate their learning to their own practice. Feedback from participants on this training program and areas for improvement; and 6) Follow up: remote pre-plan consults and/or reviews as well as post-plan analyses for several cases. Conclusions: Effective training with hands on experience followed by support after centre implementation will improve the learning curve, increase confidence, and assist radiation therapy teams to set up a breast brachytherapy program in their department. 
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FIGHTING PROSTATE CANCER WITH OUR EYES OPEN: IMPACT OF MRI STAGING ON RISK ASSESSMENT AND RADIATION THERAPY
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CARO 2016 _________________________________________________________________________________________________________ examination and transrectal ultrasound, CT and/or bone scan imaging. Increasingly, multiparametric magnetic resonance imaging (mpMRI) is being used to identify the presence, size and location of dominant intraprostatic lesions (DIL) for novel treatment approaches, such as MR-dose painted brachytherapy. This study was done to determine how frequently risk assessment was changed after mpMRI and to summarize the dosimetric data of DIL coverage for MR-dose painted brachytherapy. Methods and Materials: This study was conducted as a retrospective chart audit. Staging information, dosimetric data and demographics were collected from the electronic patient record for prostate cancer patients who had mpMRI staging prior to radiotherapy. Pre-and post-mpMRI risk assessment and dosimetric data were analyzed using descriptive statistics. Univariate analyses of demographic and staging information were done to identify factors associated with changes in risk assessment. Results: In total, 100 patients underwent mpMRI staging. Before mpMRI, 12 patients were assessed with low-risk, 47 with intermediate-and 41 with high-risk disease. After mpMRI, risk assessment changed for 11 patients; four low-risk patients changed to intermediate-risk and one low-and six intermediaterisk patients changed to high-risk. On average, reclassified patients had a larger prostate volume (Mean = 48.4cc, StDev = 10.6 versus Mean = 37.1 cc, StDev = 12.1; p = 0.004). Most patients (90/100) had a DIL identified as PiRADs 4 or 5 with an average volume of 5.4 cc. The mean boost D90% and V150% to the DIL were 131 and 69 respectively. Conclusions: Risk assessment changed after mpMRI in a small but significant proportion of the patients reviewed in this study. mpMRI is an important tool for the identification of intraprostatic lesions and the accurate staging of prostate cancer patients prior to HDR brachytherapy. Siraj Husain, Elizabeth Watt, Michael Peacock, Karen Long, Tyler Meyer University of Calgary, Calgary, AB Purpose: To validate the Hilts et al. (Brachytherapy 2015; 14:970-8 ) skin dose to 0.2 ccs' as a metric to estimate skin toxicity following breast brachytherapy with a permanent seed implant. Methods and Materials: Between November 2013 and December 2015, 25 patients were treated with a permanent Palladium Seed Implant breast brachytherapy technique 14 to 16 weeks following breast conserving surgery for Stage 0-1 breast cancer. Prescribed dose was 90Gy. Pre-op planning parameters were (PTV V100 > 95%, V200 < 40%, skin dose to 1 cm 2 was kept to < 90% of prescribed dose). Immediately following the implant (Day 0 CT) patients had a CT simulation performed to assess the implant quality. Images were transferred to the Mim Symphony treatment planning system and deformably registered to the preop plan to create a post op plan. The deformed seroma contour was modified by the treating physician where necessary, and doses to skin and PTV were evaluated. PTV V200 and CTV V100 were calculated. Skin dose to 0.2 cc was calculated and correlated with clinical signs and symptoms. Cosmetic outcomes were evaluated at 2, 4, 8, 16, 26 and 52 weeks post treatment using patient reports based on the Harvard Cosmetic Criteria. Results: Mean post-op CTV V100 and PTV V200 were 93.2 Gy and 36.2 Gy with a range of 70.2 Gy to 100 Gy and 15.8 -62.4 Gy, respectively. Mean dose to 0.2 cc of skin was 51.5 Gy with a range of 12.2 Gy to 137.2 Gy. At two and four weeks all but one patient had excellent cosmesis. At eight weeks, 17, two and one patients reported excellent, good, and fair cosmesis. The patient who reported fair continued to score fair until 52 weeks at which time she reported good. The two patients that scored "good" had Grade 1 reaction and by 16 weeks converted back to excellent. All patients who scored "excellent" at 16 weeks continued to report excellent on their subsequent visits. Only two patients had a skin 0.2 cc dose of > 100 Gy and both reported skin reactions (Grade 1 for SD 0.2 cc 137.2, and Grade 2 for SD 0.2cc of 108.1 Gy). One patient with a 0.2 cc skin dose of 34.8 Gy also developed a Grade 1 skin reaction. Conclusions: Permanent Breast Seed Implant brachytherapy delivered in a single fraction caused a low rate of early side effects and patient reported cosmetic results were good to excellent in this small group of patients. An SD 0.2cc of > 100 Gy appeared to predict skin reactions, as only one out of 23 reported Grade 1 reaction below this level and two out of two patients with a dose above this had skin reactions. Further follow up is ongoing to assess late effects and dosimetric factors that may predict favourable and less favourable outcomes. More data is needed to better predict these factors. 
CAN POST-OP DOSIMETRY PREDICT SKIN REACTIONS FOLLOWING PARTIAL BREAST RADIATIO TREATMENT USING PERMANENT PALLADIUM SEED IMPLANTS?
